HISTOGEN INC - HSTO STOCK NEWS

Histogen Inc. announced that its product HST-002 has been designated as a drug-biologic-device combination product by the FDA. This classification impacts its clinical trial timeline. The company plans to report top-line data for its HST-001 trial for androgenic alopecia in men in 4Q20. Additionally, Histogen is on track to submit an IND for HST-003, aimed at knee cartilage regeneration, also expected in 4Q20. The company focuses on restorative therapeutics and utilizes innovative technologies, but emphasizes that future results are uncertain due to various risks.

Histogen Inc. (NASDAQ: HSTO) has received a $2 million grant from the U.S. Department of Defense to fund a Phase 1/2 clinical trial for HST-003, aimed at regenerating knee cartilage in patients with focal defects. The trial involves 15 participants and will assess safety and efficacy using traditional scoring systems and MRI evaluations. The need for better knee injury treatments is highlighted, with 900,000 Americans affected annually. Histogen's innovative approach has shown promise in preclinical studies for cartilage regeneration, emphasizing its potential for both military and civilian applications.

Histogen Inc. (NASDAQ: HSTO) has announced the completion of patient dosing for the week 6 treatment point in its Phase 1b/2a clinical trial of HST-001, targeting androgenic alopecia in men. The trial involves 36 subjects and assesses safety, tolerability, and efficacy indicators. Histogen’s President, Richard W. Pascoe, expressed optimism about the upcoming top-line data results expected in Q4 2020, highlighting HST-001's potential as a first-in-class product that may stimulate new hair growth. The trial's primary endpoints will be evaluated at Week 18.

Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company, announced its participation in the HC Wainwright 22nd Annual Global Investment Conference. Richard W. Pascoe, the company's President and CEO, will present on September 15, 2020, at 11:30 a.m. Eastern Time. The presentation will be available via a live webcast, with a replay accessible for 90 days following the event on Histogen's Investors page. Histogen focuses on restorative therapeutics that promote natural biological repair, utilizing innovative technologies for various therapeutic applications.

Histogen Inc. (NASDAQ: HSTO) reported its second-quarter 2020 results, highlighting a revenue drop to $0.1 million from $1.4 million year-over-year. The decrease is attributed to lower supply order fulfillment from Allergan. In the same duration, in-process R&D expenses surged to $7.1 million, largely due to the recent reverse merger with Conatus. The company completed enrollment for the HST-001 trial for androgenic alopecia, with topline data expected in Q4 2020. Histogen also entered a $10 million stock purchase agreement with Lincoln Park Capital and appointed Susan A. Knudson as CFO.

Histogen Inc. (NASDAQ: HSTO) announced its second-quarter financial results will be released on August 13, 2020, after market close. The company specializes in developing innovative restorative therapeutics aimed at enhancing the body's natural healing processes. Histogen's proprietary technology includes cell-conditioned media and extracellular matrix materials from hypoxia-induced multipotent cells, targeting hair growth, dermal rejuvenation, joint cartilage regeneration, and spinal disk repair.

Histogen Inc. (NASDAQ: HSTO) announced that CEO Richard W. Pascoe will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 1:30 p.m. Eastern Time. The virtual event will discuss Histogen's focus on developing first-in-class restorative therapeutics aimed at enhancing natural body repair processes. Interested participants can access the live webcast through a provided link, and a replay will be available for 90 days on the company’s website. Histogen specializes in therapeutic solutions for hair growth, dermal rejuvenation, and joint cartilage regeneration.

Histogen Inc. (NASDAQ: HSTO) has entered a $10 million common stock purchase agreement with Lincoln Park Capital Fund. The initial purchase of $1 million has been executed, with Histogen retaining control over future sales. Proceeds will be utilized for working capital and general corporate purposes. The agreement prohibits Lincoln Park from short selling Histogen's stock. The purchase agreement is terminated at Histogen's discretion without penalties. Further details are in a Current Report on Form 8-K filed with the SEC.

Histogen Inc. (NASDAQ: HSTO) has successfully completed patient enrollment ahead of schedule for its Phase 1b/2a clinical trial of HST 001, aimed at treating androgenic alopecia in men. The trial involves 36 subjects enrolled using a 2:1 randomization of HST 001 to placebo, with primary endpoints evaluated at Week 18 and top-line data expected in Q4 2020. HST 001, a physician-administered therapeutic, seeks to promote new hair growth, representing a potential enhancement over existing hair loss treatments. The company emphasizes its commitment to advancing this promising product.